Fincons Group is one of the partners in the CoMPaSS-NMD project - Computational Models for new Patients Stratification Strategies of Neuromuscular Diseases, funded by the European Commission's HORIZON EUROPE programme and the Swiss State Secretariat for Education, Research, and Innovation SERI, with the objective of creating new and universal tools for diagnostic stratification and personalised treatments for patients suffering from Hereditary NeuroMuscular Diseases (HNMDs). This is a slowly progressive genetic diseases that causes long-term disability and premature death.
The project involves research centres, industrial partners and clinical centres from Italy, France, Germany, Finland and the UK as part of the European Reference Network for Rare Neurological Diseases.
The main outcome of the project, the CoMPaSS-NMD platform will be an artificial intelligence-based platform that aims to provide precise clinical characterisation and diagnosis which will have a strong impact on European field research and healthcare.
The project will provide guidelines and recommendations for patient management to offer a higher standard of care for diagnosis and prognosis as well as assistance in planning clinical trials.